IRIS
VOGRIG, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.485
AS - Asia 3.389
EU - Europa 1.603
SA - Sud America 633
Continente sconosciuto - Info sul continente non disponibili 419
AF - Africa 97
OC - Oceania 3
Totale 10.629
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.236
SG - Singapore 1.780
IT - Italia 656
CN - Cina 547
BR - Brasile 496
HK - Hong Kong 314
VN - Vietnam 268
DE - Germania 148
FR - Francia 148
RU - Federazione Russa 140
CA - Canada 117
FI - Finlandia 91
GB - Regno Unito 90
IN - India 85
KR - Corea 76
IE - Irlanda 74
BD - Bangladesh 68
AR - Argentina 60
NL - Olanda 53
JP - Giappone 37
MX - Messico 37
ES - Italia 31
UA - Ucraina 31
AT - Austria 29
ID - Indonesia 29
TR - Turchia 26
EC - Ecuador 24
PH - Filippine 23
TG - Togo 23
SE - Svezia 22
IQ - Iraq 21
ZA - Sudafrica 18
PK - Pakistan 17
CR - Costa Rica 16
CO - Colombia 15
JM - Giamaica 15
SA - Arabia Saudita 14
PL - Polonia 13
NI - Nicaragua 12
HN - Honduras 11
KZ - Kazakistan 11
LT - Lituania 11
MA - Marocco 11
VE - Venezuela 11
BE - Belgio 9
TN - Tunisia 9
TW - Taiwan 9
CL - Cile 8
GT - Guatemala 8
PE - Perù 8
PT - Portogallo 8
CZ - Repubblica Ceca 7
EG - Egitto 7
NP - Nepal 7
DZ - Algeria 6
MY - Malesia 6
PY - Paraguay 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
CH - Svizzera 5
KE - Kenya 5
KG - Kirghizistan 5
OM - Oman 5
TH - Thailandia 5
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
CU - Cuba 4
HU - Ungheria 4
PR - Porto Rico 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
DO - Repubblica Dominicana 3
EE - Estonia 3
ET - Etiopia 3
GD - Grenada 3
GR - Grecia 3
IL - Israele 3
JO - Giordania 3
LB - Libano 3
LU - Lussemburgo 3
LV - Lettonia 3
RO - Romania 3
SC - Seychelles 3
SN - Senegal 3
UY - Uruguay 3
AL - Albania 2
AU - Australia 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BO - Bolivia 2
BW - Botswana 2
CI - Costa d'Avorio 2
GP - Guadalupe 2
HT - Haiti 2
MD - Moldavia 2
PA - Panama 2
PS - Palestinian Territory 2
RS - Serbia 2
AG - Antigua e Barbuda 1
AM - Armenia 1
Totale 10.187
Salva come PNG Salva come JPEG
Città #
Singapore 594
Ashburn 484
Council Bluffs 438
San Jose 335
Hong Kong 306
Beijing 237
Boardman 167
Fairfield 136
Los Angeles 113
Lauterbourg 101
Santa Clara 90
Ho Chi Minh City 86
Dallas 79
Seoul 76
Chandler 75
Trieste 75
Dublin 74
Hefei 74
Helsinki 71
Milan 70
New York 70
Houston 67
Woodbridge 63
Seattle 61
Redondo Beach 54
Hanoi 49
Munich 49
São Paulo 48
Wilmington 46
Cambridge 41
Chicago 38
Buffalo 36
Phoenix 36
North Bergen 34
Rome 31
Frankfurt am Main 30
Ogden 29
Nuremberg 27
Montreal 26
Belluno 25
The Dalles 25
Orem 24
Venezia 24
Dearborn 23
Jacksonville 23
Lomé 23
Princeton 23
Tokyo 22
Toronto 22
Bologna 21
Atlanta 20
Ann Arbor 19
Hyderabad 19
San Francisco 19
Udine 19
London 18
Mexico City 18
Brooklyn 17
Da Nang 17
Dong Ket 17
Amsterdam 16
Tavagnacco 16
Rio de Janeiro 15
San Diego 15
Carrboro 14
Denver 14
Lappeenranta 14
Naples 14
Boston 13
Chennai 13
Philadelphia 13
Redmond 13
San José 12
Managua 11
Mumbai 11
Poplar 11
Kingston 10
Las Vegas 10
Norwalk 10
Belo Horizonte 9
Biên Hòa 9
Charlotte 9
Düsseldorf 9
Florence 9
Goiânia 9
Guarulhos 9
Haiphong 9
Portland 9
Stockholm 9
Vienna 9
Cabanatuan City 8
Guayaquil 8
Izmir 8
Johannesburg 8
Manchester 8
Miami 8
New Delhi 8
Porto Alegre 8
The Bronx 8
Baghdad 7
Totale 5.377
Salva come PNG Salva come JPEG
Nome #
Intra-carotid self-injection of alprazolam: an unusual cause of unilateral multiembolic stroke 220
Tacrolimus-induced severe headache associated with diffuse leukoencephalopathy: Evidence for an immune-mediated pathogenesis 175
Epidemiology of autoimmune versus infectious encephalitis 168
Epilepsia partialis continua revealing idelalisib-associated PML-IRIS: clinical and pathological features 154
Back to the future: encephalitis lethargica as an autoimmune disorder? 150
Epidemiology of paraneoplastic neurological syndromes: a population-based study 148
Effect of thymectomy on refractory autoimmune status epilepticus 144
Peculiar EEG signatures, ictal drinking and long-term follow-up in anti-LGI1 encephalitis 144
Serum markers as predictors of immune checkpoint inhibitors (ICI) related adverse events in a real-world scenario 141
Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis: Clues for Diagnosis 139
Central nervous system immune-related disorders after SARS-CoV-2 vaccination: a multicenter study 135
Cerebellar Ataxia With Anti-DNER Antibodies: Outcomes and Immunologic Features 133
Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination 131
Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review 131
Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review 130
Seizure specificities in patients with antibody-mediated autoimmune encephalitis 129
Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes 127
Central nervous system adverse events of immune checkpoint inhibitors 126
SOX1 antibody-related paraneoplastic neurological syndromes: clinical correlates and assessment of laboratory diagnostic techniques 120
Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes 119
Consensus Paper: Latent Autoimmune Cerebellar Ataxia (LACA) 117
Stroke-Like Presentation of Paraneoplastic Cerebellar Degeneration: a Single-Center Experience and Review of the Literature 115
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors 113
Anti-CASPR2 clinical phenotypes correlate with HLA and immunological features 111
Sudden unexpected death in epilepsy and ictal asystole in patients with autoimmune encephalitis: a systematic review 111
Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota 109
Seizures, Epilepsy, and NORSE Secondary to Autoimmune Encephalitis: A Practical Guide for Clinicians 107
Reply to "Guillain‑Barré syndrome in the COVID‑19 era another occasional cluster?": Insights from two distinct clusters of Guillain–Barré syndrome detected in Europe in the COVID-19 era 107
Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases 104
Distinct movement disorders in contactin-associated-protein-like-2 antibody-associated autoimmune encephalitis 103
Immunopathogenesis and proposed clinical score for identifying Kelch-like protein-11 encephalitis 103
Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis 100
Central nervous system complications associated with immune checkpoint inhibitors 100
Efficacy of Perampanel in Refractory and Super-Refractory Status Epilepticus with Suspected Inflammatory Etiology: A Case Series 100
Causality in COVID-19-associated stroke: a uniform case definition for use in clinical research 100
Real-Life Evaluation of the MOGAD Diagnostic Criteria: Application Challenges and Discrepancies 98
Stroke in patients with SARS-CoV-2 infection: case series 98
Motor neuron involvement in anti-Ma2-associated paraneoplastic neurological syndrome 94
Application of the anti-IgLON5 disease composite score to assess severity, clinical course, and mortality in a French cohort 92
Perampanel as add-on therapy in epilepsies with known etiology: A single center experience with long-term follow-up 91
Movement disorders in oncology: From clinical features to biomarkers 90
Relapses, Comorbidities, and Predictors of Outcome in Anti-GABAA Receptor Encephalitis 90
Predictors and Clinical Characteristics of Relapses in LGI1-Antibody Encephalitis 89
Revisiting anti-Hu paraneoplastic autoimmunity: phenotypic characterization and cancer diagnosis 88
Glial Fibrillary Acidic Protein Autoimmunity: A French Cohort Study 88
18F-FDG PET brain findings in disease-discordant monozygotic mosaic twins with Cri du Chat (5p-) syndrome 88
Bornavirus associated with fatal human encephalitis 87
Response to Letter to the Editor on the article “Acute disseminated encephalomyelitis after SARS-CoV-2 vaccination” 87
Associations between HLA and autoimmune neurological diseases with autoantibodies 86
Role of LGI1 protein in synaptic transmission: From physiology to pathology 86
Anti-Hu-associated paraneoplastic syndromes triggered by immune-checkpoint inhibitor treatment 86
HLA and immunological features of SARS-CoV-2-induced Guillain-Barré syndrome 86
Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration 86
Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors 85
A systematic study of stereotypy in epileptic seizures versus psychogenic seizure-like events 85
Distinguishing seizures in autoimmune limbic encephalitis from mesial temporal lobe epilepsy with hippocampal sclerosis: Clues of a temporal plus network 84
SARS-CoV-2-related encephalitis with prominent parkinsonism: clinical and FDG-PET correlates in two patients 84
Adenovirus COVID-19 Vaccines and Guillain–Barré Syndrome with Facial Paralysis 82
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD 82
Prevalence and Trajectories of Post-COVID-19 Neurological Manifestations: A Systematic Review and Meta-Analysis 81
Unclear association between COVID-19 and Guillain-Barré syndrome 81
Bilateral carotid artery dissection in a SARS-CoV-2 infected patient: causality or coincidence? 80
Editorial: Neuroglial antibodies: From clinical associations to pathophysiological investigations 79
Eating reflex epilepsy of presumed autoimmune etiology after SARS-CoV-2 vaccination 78
Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors 78
Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA B R Antibodies 78
Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors 78
Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France 78
Cytokine dynamics and targeted immunotherapies in autoimmune encephalitis 78
Evaluation and treatment approaches for neurological post-acute sequelae of COVID-19: A consensus statement and scoping review from the global COVID-19 neuro research coalition 77
Novelties in Autoimmune and Paraneoplastic Cerebellar Ataxias: Twenty Years of Progresses 77
Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors. Focus on Chronic Toxicities 77
Transient Neurological Symptoms Preceding Cerebellar Ataxia with Glutamic Acid Decarboxylase Antibodies 76
Glioblastoma as differential diagnosis of autoimmune encephalitis 75
Paraneoplastic encephalitis: clinically based approach on diagnosis and management 75
Neuroimmune disorders in COVID-19 75
Anti-Ma-associated encephalomyeloradiculopathy in a patient with pleural mesothelioma 75
Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience 75
Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis 74
How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update 74
Prognostic Value of Persistent CSF Antibodies at 12 Months in Anti-NMDAR Encephalitis 74
Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia 74
Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes 74
Neurological immune-related adverse events of immune checkpoint inhibitors: clinical and hematological risk factors 74
Reader Response: Prolonged Unconsciousness Following Severe COVID-19 74
Different Genetic Signatures of Small-Cell Lung Cancer Characterize Anti-GABABR and Anti-Hu Paraneoplastic Neurological Syndromes 74
Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity 73
Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Practical recommendations for diagnosis and management 73
Proceedings of the “International Congress on Structural Epilepsy & Symptomatic Seizures” (STESS, Gothenburg, Sweden, 29–31 March 2023) 72
Stroke in patients with COVID-19: Clinical and neuroimaging characteristics 72
Probable dysimmune epilepsia partialis continua manifesting as epileptic moving toes syndrome: electroclinical features of a challenging case 70
Corticospinal tract hyperintensity in patients with LGI1-antibody encephalitis and other central nervous system disorders with neuroglial antibodies 69
Nystagmus and lower extremity hyperalgesia after colectomy 68
Immunomodulation in the acute phase of autoimmune encephalitis 67
Iatrogenic NORSE: Immune checkpoint inhibitor-related anti-GFAP autoimmune astrocytopathy 67
Distinctive clinical presentation and pathogenic specificities of anti-AK5 encephalitis 66
Prognosis of status epilepticus in adults: recent advances and future directions 65
Clinical specificities and outcome of LGI1-antibody encephalitis according to age, sex and HLA 63
Dramatic response to delayed treatment with tocilizumab in new-onset refractory status epilepticus 63
Paraneoplastic Neurologic Syndromes Associated With Merkel Cell Carcinoma 62
Totale 9.589
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.498
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.498
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022113 0 0 0 0 2 0 13 4 3 20 48 23
2022/2023528 20 18 3 19 176 179 4 8 31 6 17 47
2023/2024343 28 22 5 24 40 18 9 31 44 57 29 36
2024/20252.297 85 140 93 70 71 83 110 104 294 240 404 603
2025/20264.511 349 406 415 552 538 302 556 160 274 352 337 270
2026/20272.081 246 401 551 883 0 0 0 0 0 0 0 0
Totale 10.629